aztreonam (azactam) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Aztreonam is the first monocyclic beta-lactam antibiotic (monobactam) originally isolated from Chromobacterium violaceum. Aztreonam has a high affinity for the protein-binding protein 3 (PBP-3) of aerobic gram-negative bacteria. Most of these organisms are inhibited and killed at low concentrations of the drug. Aztreonam must be administered as an intravenous or intramuscular injection (AZACTAM®), or inhaled (CAYSTON®). Aztreonam for injection is indicated for the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract, lower respiratory tract, skin and skin-structure, intra-abdominal and gynecologic infections as well as for septicemia. Aztreonam for inhalation solution is indicated to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.   NCATS

Chemistry

  • SMILES: C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
  • InChIKey: WZPBZJONDBGPKJ-VEHQQRBSSA-N
  • Mol. Mass: 435.433
  • ALogP: -1.17
  • ChEMBL Molecules:
    aztreonam  
    None  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$21.3390 - $57.1850
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-({[(1z)-1-(2-amino-1,3-thiazol-4-yl) -2- {[(2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino} -2- oxoethylidene]amino}oxy)-2-methylpropanoic acid | azactam | azonam | azthreonam | aztreon | aztreonam | aztréonam | aztreonam lysine | aztreonam lysine [usan] | aztreonamum | cayston | monobactam | nebactam | primbactam | so-26776 | sq-26776 | (z,)-2-((((2-amino-4-thiazolyl)(((2s,3s,)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid

Organizations (47)

Research & Development (41)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (28)

Approved Indications (9)


 

Infections

Intraabdominal Infections (approved 1986)

Pneumonia

Pyelonephritis

Respiratory Tract Infections (approved 1986)

Sepsis

Skin Diseases, Bacterial (approved 1986)

Urinary Tract Infections

Vaginal Diseases (approved 1986)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Bacterial Infections (Phase 3)

Bronchiectasis (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Cystic Fibrosis (Phase 4)

Diabetic Foot (Phase 4)

Enterobacteriaceae Infections (Phase 3)

Gonorrhea (Phase 2/Phase 3)

Gram-Negative Bacterial Infections (Phase 2)

Healthcare-Associated Pneumonia (Phase 3)

Healthy Volunteers (Phase 1)

Infections ()

Lung Transplantation (Phase 4)

Osteomyelitis (Phase 2)

Pneumonia, Ventilator-Associated (Phase 3)

Pseudomonas (Phase 4)

Pseudomonas aeruginosa (Phase 2)

Pseudomonas Infections (Phase 3)

Pyelonephritis (Phase 3)

Renal Insufficiency (Phase 1)

Respiratory Tract Infections (Phase 3)

Skin Diseases, Infectious (Phase 3)

Soft Tissue Infections (Phase 3)

Urinary Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 39
  • # of Trial Organizations: 41

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue